50 unknown, 41 completed, 27 recruiting, 15 not yet recruiting. 53 Phase 2, 35 Not applicable, 19 Phase 1, 14 Phase 3, 7 Phase 4.
Follow HCC: new trials by email Literature Review of HCC trials Research Report on HCC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment Transarterial chemoembolization, durvalumab and tremelimumab - HCC, Tace | Phase 2 | Not yet recruiting | Chang Gung Memorial Hospital | 90 | 2026-09-15 | 2026-08-06 |
| Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporation, Electroporation Device, INO-9012 - HCC | Phase 2 | Recruiting | Geneos Therapeutics | 90 | 2026-09-01 | 2026-09-23 |
| A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC VRT106, VRT106 in combination with camrelizumab and apatinib, Investigator's Choice of Standard of Care - HCC | Phase 2 / Phase 3 | Recruiting | Guangzhou Virotech Pharmaceutical Co., Ltd. | 66 | 2026-05-13 | 2026-05-15 |
| TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular Carcinoma TACE, HAIC, PD-1inhibitors - HCC | Not yet recruiting | Tongji Hospital | 364 | 2026-01-31 | 2026-01-14 | |
| Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma PD-1 Inhibitors - HCC, Adjuvant Therapy | Not yet recruiting | Tongji Hospital | 300 | 2026-01-31 | 2026-01-30 | |
| Preliminary Evaluation of Clinical Application of SPECT Imaging Targeting GPC3 131I-aGPC3 - HCC, SPECT-CT | Not applicable | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 6 | 2026-01-30 | 2026-01-20 |
| Accumulation of Lipid Droplets as an Underlying Cause of the Progression of Fatty Liver Disease to Liver Cancer Comprehensive Genomic and Transcriptomic Profiling, Patient-Derived Human Liver Organoid (HLO) Development, AI-Driven Digital Pathology (HistoIndex) - HCC, MASLD | Not applicable | Active not recruiting | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 35500 | 2026-01-29 | 2026-08-20 |
| REGULUS: MRI-guided Adaptive SABR for Liver Cancers MRI-guided adaptive stereotactic ablative body radiotherapy (SABR) - Liver Cancer, Intrahepatic Cholangiocarcinoma | Phase 2 | Recruiting | Stanford University | 62 | 2026-01-23 | 2026-02-09 |
| TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol - HCC, Liver Cirrhosis | Phase 2 | Not yet recruiting | Tongji Hospital | 78 | 2025-12-31 | 2026-01-20 |
| Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC Adjuvant PD-1 inhibitors, Active monitoring - HCC, Minimal Residual Disease | Not applicable | Not yet recruiting | Tongji Hospital | 276 | 2025-12-31 | 2026-01-20 |
| Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular SBRT, Sintilimab, Surgery - HCC | Phase 2 | Not yet recruiting | Lei ZHAO | 110 | 2025-12-28 | 2026-01-20 |
| Y-90 Treatment Response Using Transarterial Radioembolization Lumason, Sonazoid - HCC, Hepatocellular Carcinoma | Phase 2 | Recruiting | Thomas Jefferson University | 30 | 2025-09-11 | 2026-06-10 |
| A Clinical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Patients With Initially Potentially Resectable Hepatocellular Carcinoma (ITBHaic Study) lparomlimab and Tuvonralimab Injection in Combination with HAIC and bevacizumab - HCC | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 34 | 2025-09-10 | 2025-08-13 |
| Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma Pracytarabine, regorafenib - HCC | Phase 2 / Phase 3 | Active not recruiting | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | 60 | 2025-09-01 | 2025-12-31 |
| Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma lparomlimab and Tuvonralimab Injection in Combination with TACE and Lenvatinib - HCC | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 29 | 2025-08-22 | 2025-08-29 |
| A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC Yttrium [90Y] Microsphere Injection, Conventional transcatheter arterial chemoembolization, Camrelizumab - HCC | Phase 2 | Recruiting | GrandPharma (China) Co., Ltd. | 120 | 2025-08-22 | 2026-01-12 |
| HOPE Against Cancer Recurrence in HCC Hypothermic oxygenated perfusion, Conventional cold storage - Liver Transplantation, HCC | Phase 4 | Recruiting | Philipp Dutkowski | 220 | 2025-08-01 | 2025-12-16 |
| SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis Radiotherapy, Atezolizumab plus Bevacizumab - HCC | Phase 2 | Recruiting | Chinese University of Hong Kong | 40 | 2025-07-10 | 2026-03-04 |
| A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC AK104+lenvatinib, lenvatinib - HCC, Hepatocellular Carcinoma | Phase 2 | Not yet recruiting | Akeso | 120 | 2025-06-25 | 2025-05-22 |
| Effect of the HCC Liver-Link Intervention Liver Link - HCC, Racial Disparities | Not applicable | Recruiting | Indiana University | 40 | 2025-06-10 | 2026-06-05 |
Showing 20 of 152. Sign in to see all of them.
Carcinoma, Hepatocellular (40) · Liver Neoplasms (17) · Recurrence (10) · Liver Cirrhosis (7) · Neoplasm Metastasis (5) · Neoplasms (4) · Cholangiocarcinoma (3) · Fibrosis (3) · Carcinoma (2) · Carcinoma, Renal Cell (2) · Colorectal Neoplasms (2) · Genetic Predisposition to Disease (2) · Hepatitis C (2) · Hypertension, Portal (2) · Liver Diseases (2)
Digestive System Diseases (56) · Liver Diseases (52) · Neoplasms (50) · Neoplasms by Site (50) · Digestive System Neoplasms (48) · Neoplasms by Histologic Type (44) · Adenocarcinoma (43) · Neoplasms, Glandular and Epithelial (43) · Carcinoma (41) · Liver Neoplasms (29) · Pathologic Processes (28) · Pathological Conditions, Signs and Symptoms (28) · Disease Attributes (13) · Fibrosis (7) · Neoplastic Processes (6)
lenvatinib (12) · Sorafenib (10) · Bevacizumab (7) · Hepatectomy (7) · Nivolumab (6) · Radiotherapy (5) · atezolizumab (5) · Immune Checkpoint Inhibitors (4) · Radiosurgery (4) · sintilimab (4) · Arginine (3) · Chemoembolization, Therapeutic (3) · Radiofrequency Ablation (3) · apatinib (3) · camrelizumab (3)
Seoul National University Hospital (8) · Chen Xiaoping (7) · Tongji Hospital (7) · The First Affiliated Hospital of Zhengzhou University (5) · Assiut University (3) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (3) · Southwest Hospital, China (3) · The University of Hong Kong (3) · Tianjin Medical University Cancer Institute and Hospital (3) · Ain Shams University (2) · Akeso (2) · Anhui Provincial Hospital (2) · Chinese University of Hong Kong (2) · Geneos Therapeutics (2) · Icahn School of Medicine at Mount Sinai (2)
China (52) · United States (27) · South Korea (12) · Hong Kong (10) · Italy (10) · France (5) · Taiwan (5) · Australia (4) · Germany (4) · Netherlands (4) · Canada (3) · Egypt (3) · New Zealand (3) · Spain (3) · Austria (2)
Jeong Min Lee, MD (8) · Wanguang Zhang (2) · Xiaoping Chen (2) · AbdelRahman Elnaggar, Prof. (1) · Aldar Bourinbaiar, MD/PhD (1) · Alex Befeler, MD (1) · Alshaimaa Rafat, MD (1) · Arndt Vogel, Prof. Dr. (1) · Avnish Bhatia, MD (1) · Bachir Taouli, MD (1) · Baorui Liu, M.D & Ph.D (1) · Benjamin Oshrine (1) · Chi Leung Chiang, Chiang (1)
PMID 12761382, PMID 15784668, PMID 16542288, PMID 18820248, PMID 19212170, PMID 19394816, PMID 19932906, PMID 20091629, PMID 20175765, PMID 20331336, PMID 21544812, PMID 21782772, PMID 22424438, PMID 23333451, PMID 24691105, PMID 24720346, PMID 25135008, PMID 25539238, PMID 25625806, PMID 25918260, PMID 25965437, PMID 26607931, PMID 26707365, PMID 26830614, PMID 27448609, PMID 27481188, PMID 28130846, PMID 28476736, PMID 28692197, PMID 28989060, PMID 29018942, PMID 29246586, PMID 29425931, PMID 29624699, PMID 29628281, PMID 30251931, PMID 31041073, PMID 31145350, PMID 31210614, PMID 31413923, PMID 31853685, PMID 31858203, PMID 31917765, PMID 32166493, PMID 33079867, PMID 34326839, PMID 34367949, PMID 34638285, PMID 34774638, PMID 34840773
2019 (1), 2023 (1), K23MD018090 (1), R21CA303648 (1)